As Bcl-2 upregulation has been implicated in resistance mechanisms to other therapeutic agents, such as cisplatin, in multiple cancer types, there is great potential to use NuBCP-9 enabled Bcl-2 functional conversion to treat an array of therapy resistant cancers [14, 33, 55, 56]. Here, BCL2 is linked to cancer.